IKNA (Ikena) Forward P/E Multiple

Official company branding of Ikena Oncology (IKNA)

Ikena Oncology, Inc. (IKNA) relies on patent protection for its targeted therapy developments, where success is driven by the precision of clinical data. The company's forward P/E clearly demonstrates the valuation dynamics, with 0.00 representing the current level of this metric. Management is betting on biomarkers for precision treatment, while a solid liquidity reserve ensures financial stability as the company explores new strategic business development scenarios.

ikenaoncology.com - IKNA Forward P/E Multiple (period 07/04/2022 - 08/09/2025)

Summary analytical data breakdowns for Ikena Oncology, Inc. (IKNA)

- current price and projected stock value:
Basic company analysis:IKNA Ikena Oncology Inc.
Brand item of Ikena

Ikena Oncology, Inc. (IKNA) develops targeted cancer therapies within a protected U.S. scientific environment, which minimizes external business risks. The ratio of the current share price to projected earnings for the coming year, represented by the company's forward P/E NTM, allows for an assessment of market expectations and the identification of potential valuation discrepancies relative to the asset's future profitability.

Analysis of competing companies

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio AONC|BGNE (BeiGene Ltd) - Forward P/E Multiple|CKPT (Checkpoint Therapeutics, Inc) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ELEV|Projected Price to Earnings iCAD Corp ICAD|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple